SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Pankaj Puri, Anil C. Anand, Vivek A. Saraswat, Subrat K. Acharya, Shiv K. Sarin, Radha K. Dhiman, Rakesh Aggarwal, Shivaram P. Singh, Deepak Amarapurkar, Anil Arora, Mohinish Chhabra, Kamal Chetri, Gourdas Choudhuri, Vinod K. Dixit, Ajay Duseja, Ajay K. Jain, Dharmesh Kapoor, Premashis Kar, Abraham Koshy, Ashish Kumar, Kaushal Madan, Sri P. Misra, Mohan V.G. Prasad, Aabha Nagral, Amarendra S. Puri, R. Jeyamani, Sanjiv Saigal, Samir Shah, Praveen K. Sharma, Ajit Sood, Sandeep Thareja, Manav Wadhawan, Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India, Journal of Clinical and Experimental Hepatology, 2014, 4, 2, 117

    CrossRef

  2. 2
    Craig E. Gordon, Jean Francis, Hepatitis C Treatment in Dialysis Patients: Is a New Dawn Approaching?, American Journal of Kidney Diseases, 2014, 64, 2, 178

    CrossRef

  3. 3
    Patrizia Burra, Kryssia I. Rodríguez-Castro, Francesco Marchini, Luciana Bonfante, Lucrezia Furian, Alberto Ferrarese, Alberto Zanetto, Giacomo Germani, Francesco Paolo Russo, Marco Senzolo, Hepatitis C virus infection in end-stage renal disease and kidney transplantation, Transplant International, 2014, 27, 9
  4. 4
    KASL clinical practice guidelines: Management of Hepatitis C, Clinical and Molecular Hepatology, 2014, 20, 2, 89

    CrossRef

  5. 5
    Kan Kikuchi, Takashi Akiba, Kosaku Nitta, Ikuto Masakane, Ryoichi Ando, Namiki Izumi, Masanori Atsukawa, Chikao Yamazaki, Fumi Kato, Naoki Hotta, Yoshihiro Tominaga, Etsuro Orito, Kazuhiko Hora, Masaki Nagasawa, Hiroshi Kasahara, Masanori Kawaguchi, Hiroyuki Kimura, Norisato Ikebe, Hideki Kawanishi, Misaki Moriishi, Kenichiro Shigemoto, Takashi Harada, Hideki Hirakata, Hiroshi Watanabe, Tsuyoshi Nosaki, Hirohito Tsubouchi, Michio Imawari, Tadao Akizawa, Multicenter Study of Pegylated Interferon α-2a Monotherapy for Hepatitis C Virus-Infected Patients on Hemodialysis: REACH Study, Therapeutic Apheresis and Dialysis, 2014, 18, 6
  6. 6
    David Callau Monje, Niko Braun, Joerg Latus, Kerstin Amann, Mark Dominik Alscher, Martin Kimmel, Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury, Case Reports in Nephrology, 2014, 2014, 1

    CrossRef

  7. 7
    Clara T. M. M. de Kanter, Joost P. H. Drenth, Joop E. Arends, Henk W. Reesink, Marc van der Valk, Robert J. de Knegt, David M. Burger, Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations, Clinical Pharmacokinetics, 2014, 53, 5, 409

    CrossRef

  8. 8
    Po-Lin Tseng, Te-Chuan Chen, Yu-Shu Chien, Chao-Hung Hung, Yi-Hao Yen, Kuo-Chin Chang, Ming-Chao Tsai, Ming-Tsung Lin, Chien-Te Lee, Chien-Heng Shen, Tsung-Hui Hu, Efficacy and Safety of Pegylated Interferon Alfa-2b and Ribavirin Combination Therapy Versus Pegylated Interferon Monotherapy in Hemodialysis Patients: A Comparison of 2 Sequentially Treated Cohorts, American Journal of Kidney Diseases, 2013, 62, 4, 789

    CrossRef

  9. 9
    Fabrizio Fabrizi, Hepatitis C Virus Infection and Dialysis: 2012 Update, ISRN Nephrology, 2013, 2013, 1

    CrossRef

  10. 10
    Khalid Alsaran, Alaa Sabry, Azeb Molhem, Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience, Renal Failure, 2013, 35, 10, 1305

    CrossRef

  11. 11
    J. Levitsky, K. Doucette, Viral Hepatitis in Solid Organ Transplantation, American Journal of Transplantation, 2013, 13, s4
  12. 12
    Şükran Köse, Süheyla Serin Senger, Gürsel Ersan, Gülsün Çavdar, Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C, Clinical and Experimental Nephrology, 2013, 17, 1, 115

    CrossRef

  13. 13
    Mohammad A. B. Al-Freah, Zeino Zeino, Michael A. Heneghan, Management of Hepatitis C in Patients with Chronic Kidney Disease, Current Gastroenterology Reports, 2012, 14, 1, 78

    CrossRef

  14. 14
    Samir Mohindra, Narayan Prasad, Treatment of hepatitis C in renal failure, Clinical Queries: Nephrology, 2012, 1, 3, 236

    CrossRef

  15. 15
    Hye Jin Tae, Dae Won Jun, Jong Wook Choi, Woong Jun Kim, Bong Young Kim, Joo Hyun Sohn, Min Ho Lee, A Case of Pegylated Interferon Alpha-2a Monotherapy in a Peritoneal Dialysis Patient with Chronic Hepatitis C, The Korean Journal of Gastroenterology, 2011, 58, 2, 107

    CrossRef

  16. You have free access to this content16
    P. Deltenre, C. Moreno, A. Tran, I. Ollivier, F. Provôt, F. Stanke, M. Lazrek, H. Castel, V. Canva, A. Louvet, M. Colin, F. Glowacki, S. Dharancy, J. Henrion, M. Hazzan, C. Noel, P. Mathurin, Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy, Alimentary Pharmacology & Therapeutics, 2011, 34, 4
  17. 17
    F. Fabrizi, V. Dixit, P. Martin, P. Messa, Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials, Journal of Viral Hepatitis, 2011, 18, 7
  18. 18
    Julio A. Gutierrez, Heather M. Patton, Hepatitis C Virus and End Stage Renal Disease, Current Hepatitis Reports, 2011, 10, 3, 196

    CrossRef

  19. 19
    Olav Dalgard, Zbigniew Konopski, Franziskus Bosse, Berit Nordstrand, Per Sandvei, Lars Karlsen, Jon Florholmen, Astrid Rojahn, Rune Almaas, Steinar Skrede, Arne Eskesen, Bjørn Myrvang, Hepatitt C - utredning og behandling, Tidsskrift for Den norske legeforening, 2011, 131, 1, 2

    CrossRef

  20. 20
    Markus Peck–Radosavljevic, John Boletis, Fatih Besisik, Maria Lúcia Ferraz, Laurent Alric, Didier Samuel, Diethelm Messinger, Andreas Tietz, Hugo Cheinquer, Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease, Clinical Gastroenterology and Hepatology, 2011, 9, 3, 242

    CrossRef

  21. 21
    Mahmoud A. Khattab, Peter Ferenci, Stephanos J. Hadziyannis, Massimo Colombo, Michael P. Manns, Piero L. Almasio, Rafael Esteban, Ayman A. Abdo, Stephen A. Harrison, Nazir Ibrahim, Patrice Cacoub, Mohammed Eslam, Samuel S. Lee, Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel, Journal of Hepatology, 2011, 54, 6, 1250

    CrossRef

  22. 22
    Khalid Alsaran, Alaa Sabry, Naila Shaheen, Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience, International Urology and Nephrology, 2011, 43, 3, 865

    CrossRef

  23. 23
    Markus Peck–Radosavljevic, Reply, Clinical Gastroenterology and Hepatology, 2011, 9, 11, 1005

    CrossRef

  24. 24
    A. Giguere, A. Anas, T. Nasser, M.H. Hassan, U. Ahmed, N. Beejay, M. Nouh, M. Khalowf, A. Saleh, A. Khan, M. Attia, G. El-Azab, Treatment of hepatitis C virus infection in patients on maintenance hemodialysis: A single United Arab Emirates center experience, European Journal of Internal Medicine, 2011, 22, 6, 582

    CrossRef

  25. 25
    Chen-Hua Liu, Jia-Horng Kao, Treatment of hepatitis C virus infection in patients with end-stage renal disease, Journal of Gastroenterology and Hepatology, 2011, 26, 2
  26. 26
    Ana Maria Sandri, Usama Elewa, John J. Poterucha, Fernando C. Fervenza, Treatment of Hepatitis C-Mediated Glomerular Disease, Nephron Clinical Practice, 2011, 119, 2, c121

    CrossRef

  27. 27
    Sanjay Kulkarni, Tamar H. Taddei, When should a hepatitis C-positive ESRD patient receive a renal transplant?, Seminars in Dialysis, 2011, 24, 4
  28. 28
    Nihon Toseki Igakkai Zasshi, 2011, 44, 6, 517

    CrossRef

  29. 29
    Mohamed Eida, Chronic hepatitis C genotype 4 treatment in chronic haemodialysis patients: A retrospective study, Arab Journal of Gastroenterology, 2010, 11, 2, 83

    CrossRef

  30. 30
    Fabrizio Fabrizi, Paul Martin, Health Care–Associated Transmission of Hepatitis B and C Viruses in Hemodialysis Units, Clinics in Liver Disease, 2010, 14, 1, 49

    CrossRef

  31. 31
    Marina Berenguer, Victoria Aguilera, Management of Hepatitis C in Patients with End-stage Renal Disease, Current Hepatitis Reports, 2010, 9, 1, 38

    CrossRef

  32. 32
    Fabrizio Fabrizi, Vivek Dixit, Piergiorgio Messa, Paul Martin, Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: Meta-analysis of clinical trials, Journal of Medical Virology, 2010, 82, 5
  33. 33
    S. S. Tan, M. R. Abu Hassan, A. Abdullah, B. P. Ooi, T. Korompis, M. I. Merican, Safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2b in the treatment of haemodialysis patients with chronic hepatitis C, Journal of Viral Hepatitis, 2010, 17, 6
  34. 34
    T. Werner, Bashar Aqel, Vijayan Balan, Thomas Byrne, Elizabeth Carey, David Douglas, Raymond L. Heilman, Jorge Rakela, Kristin Mekeel, Kunam Reddy, Hugo E. Vargas, Treatment of Hepatitis C in Renal Transplantation Candidates: A Single-Center Experience, Transplantation, 2010, 90, 4, 407

    CrossRef

  35. You have free access to this content35
    Marc G. Ghany, Doris B. Strader, David L. Thomas, Leonard B. Seeff, Diagnosis, management, and treatment of hepatitis C: An update, Hepatology, 2009, 49, 4
  36. 36
    Andrew Aronsohn, Nancy Reau, Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients, Journal of Clinical Gastroenterology, 2009, 43, 7, 661

    CrossRef

  37. 37
    K. Rajender Reddy, David R. Nelson, Stefan Zeuzem, Ribavirin: Current role in the optimal clinical management of chronic hepatitis C, Journal of Hepatology, 2009, 50, 2, 402

    CrossRef

  38. 38
    Michiko Shindo, Treatment of chronic hepatitis C: present and future, Kanzo, 2009, 50, 7, 345

    CrossRef

  39. 39
    Sukran Kose, Alp Gurkan, Fatih Akman, Mehmet Kelesoglu, Ufuk Uner, Treatment of hepatitis C in hemodialysis patients using pegylated interferon α-2a in Turkey, Journal of Gastroenterology, 2009, 44, 4, 353

    CrossRef

  40. 40
    J. Levitsky, K. Doucette, Viral Hepatitis in Solid Organ Transplant Recipients, American Journal of Transplantation, 2009, 9,
  41. 41
    Emuejevoke J. Okoh, Jay R. Bucci, James F. Simon, Stephen A. Harrison, HCV in Patients With End-Stage Renal Disease, The American Journal of Gastroenterology, 2008, 103, 8, 2123

    CrossRef

  42. 42
    Paul Martin, Fabrizio Fabrizi, Hepatitis C virus and kidney disease, Journal of Hepatology, 2008, 49, 4, 613

    CrossRef

  43. 43
    Seema Baid-Agrawal, Manuel Pascual, Darius Moradpour, Ulrich Frei, Nina Tolkoff-Rubin, Hepatitis C virus infection in haemodialysis and kidney transplant patients, Reviews in Medical Virology, 2008, 18, 2
  44. 44
    F. Fabrizi, V. Dixit, P. Messa, P. Martin, Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials, Journal of Viral Hepatitis, 2008, 15, 2
  45. 45
    I. Mimura, Y. Ishibashi, R. Tateishi, S. Kaname, T. Fujita, Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C, Clinical Kidney Journal, 2008, 1, 4, 233

    CrossRef

  46. 46
    Devasmita Choudhury, Cynthia Luna-Salazar, Preventive health care in chronic kidney disease and end-stage renal disease, Nature Clinical Practice Nephrology, 2008, 4, 4, 194

    CrossRef

  47. 47
    R. van Leusen, A. C. Tan, Reply, Nephrology Dialysis Transplantation, 2008, 23, 7, 2430

    CrossRef

  48. 48
    S. C. Akhan, B. Kalender, M. Ruzgar, The Response to Pegylated Interferon Alpha 2a in Haemodialysis Patients with Hepatitis C Virus Infection, Infection, 2008, 36, 4, 341

    CrossRef

  49. 49
    C. Fournier, C. Souvignet, P. Merle, P. Miailhes, P. Lack, C. Trepo, Traitement de l'hépatite C, EMC - Hépatologie, 2008, 3, 1, 1

    CrossRef

  50. 50
    Marina Berenguer, Treatment of chronic hepatitis C in hemodialysis patients, Hepatology, 2008, 48, 5
  51. 51
    Ulrich Kunzendorf, Ekkehard Ziegler, Facharzt Nephrologie, 2008,

    CrossRef

  52. 52
    István Tornai, János Mátyus, A hepatitis C-vírusfertőzés terápiája vesepótló kezelésben részesülő betegekben, Orvosi Hetilap, 2007, 148, 11, 489

    CrossRef

  53. 53
    Roberto J. Firpi, David R. Nelson, Current and Future Hepatitis C Therapies, Archives of Medical Research, 2007, 38, 6, 678

    CrossRef

  54. 54
    Shintaro Takaki, Yoshiiku Kawakami, Michio Imamura, Hiroshi Aikata, Shoichi Takahashi, Hiroto Ishihara, Keiji Tsuji, Shiomi Aimitsu, Hiroiku Kawakami, Toshio Nakanishi, Mikiya Kitamoto, Takashi Moriya, Kenichi Satoh, Kazuaki Chayama, Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with Pegylated Interferon-α and Ribavirin, Intervirology, 2007, 50, 6, 439

    CrossRef

  55. 55
    Charles S. Whang, Ke-Qin Hu, Hepatitis C in patients with chronic kidney disease: Course and management, Current Hepatitis Reports, 2007, 6, 3, 96

    CrossRef

  56. 56
    Władysław SUŁOWICZ, Andrzej RADZISZEWSKI, Eve CHOWANIEC, Hepatitis C virus infection in dialysis patients, Hemodialysis International, 2007, 11, 3
  57. 57
    CHEN-HUA LIU, CHUN-JEN LIU, JIA-HORNG KAO, Interferon-based therapy for dialysis patients with chronic hepatitis C: Progress and challenges (Editorial), Nephrology, 2007, 12, 1
  58. 58
    Fabrizio Fabrizi, Giovanna Lunghi, Sri Venkatesh Ganeshan, Paul Martin, Piergiorgio Messa, Reviews: Hepatitis C Virus Infection and the Dialysis Patient, Seminars in Dialysis, 2007, 20, 5
  59. 59
    Maria Rendina, Antonio Schena, Nicola Maurizio Castellaneta, Francesco Losito, Anna Cinzia Amoruso, Giovanni Stallone, Francesco Paolo Schena, Alfredo Di Leo, Antonio Francavilla, The treatment of chronic hepatitis C with peginterferon alfa-2a (40kDa) plus ribavirin in haemodialysed patients awaiting renal transplant, Journal of Hepatology, 2007, 46, 5, 768

    CrossRef

  60. 60
    Harmit Kalia, Patricia M. Lopez, Paul Martin, Treatment of HCV in Patients with Renal Failure, Archives of Medical Research, 2007, 38, 6, 628

    CrossRef

  61. 61
    Aleksandar Sikole, Pavlina Dzekova, Nexhmi Selja, Magdalena Gaseva, Igor G. Nikolov, Mustafa Zabzun, Sheriat Muharemi, Arben Asani, Vili Amitov, Sami Mena, Violeta Grunevska, Ljubomir Ivanovski, Momir Polenakovic, Treatment of Hepatitis C in Hemodialysis Patients with Pegylated Interferon α-2a as Monotherapy, Renal Failure, 2007, 29, 8, 961

    CrossRef

  62. 62
    István Tornai, János Mátyus, Treatment of Hepatitis C Virus Infection in Patients before and after Renal Transplantation, Hungarian Medical Journal, 2007, 1, 2, 225

    CrossRef

  63. 63
    Jessica Tan, Anna SF Lok, Update on viral hepatitis: 2006, Current Opinion in Gastroenterology, 2007, 23, 3, 263

    CrossRef

  64. 64
    F. FABRIZI, G. LUNGHI, V. DIXIT, P. MARTIN, Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients, Alimentary Pharmacology & Therapeutics, 2006, 24, 10
  65. 65
    Goran Hauser, Tahany Awad, Kristian Thorlund, Davor Štimac, Mahasen Mabrouk, Christian Gluud, Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C, The Cochrane Library,